CLAIMS

What is claimed is:

1. Use of apoaequorin in the manufacture of a medicament for preconditioning neurons to reduce neuronal inflammation in a subject.

2. The use according to claim 1, wherein the apoaequorin is to be administered by injection.

3. The use according to claim 1, wherein the apoaequorin is to be administered by oral delivery.

4. The use according to claim 3, wherein the apoaequorin is in a unit dosage form selected from a tablet or capsule.

5. The use according to claim 3 or 4, wherein the apoaequorin is in the form of a nutraceutical composition.

6. Use of apoaequorin in the manufacture of a medicament for reducing Tumor Necrosis Factor α protein level in a subject.

7. The use according to claim 6, wherein the apoaequorin is to be administered by injection.

8. The use according to claim 6, wherein the apoaequorin is to be administered by oral delivery.

9. The use according to claim 8, wherein the apoaequorin is in a unit dosage form selected from a tablet or capsule.

10. The use according to claim 8, wherein the apoaequorin is in the form of a nutraceutical composition.